8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Oct 26, 2009)

Filed October 26, 2009For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed a Form 8-K on October 26, 2009, to report its consolidated financial results for the quarter ended September 30, 2009. This filing primarily serves to incorporate by reference a press release issued on the same date, which contains the detailed financial outcomes. Investors should refer to the attached press release (Exhibit 99.1) for specific figures regarding revenue, expenses, earnings, and any significant operational updates from the third quarter of 2009. The announcement is crucial for understanding the company's financial health and performance trajectory during that period. While the 8-K itself is a brief filing, it signifies the official disclosure of Vertex's quarterly financial performance. Investors are encouraged to review the referenced press release for comprehensive insights into the company's financial condition and results of operations.

Key Highlights

  • 1Vertex Pharmaceuticals Inc. reported its third-quarter 2009 financial results on October 26, 2009, via a Form 8-K filing.
  • 2The 8-K filing incorporates by reference a press release (Exhibit 99.1) dated October 26, 2009, containing the detailed financial results.
  • 3Investors need to consult the press release for specific financial data such as revenue, net income, and earnings per share for the quarter ended September 30, 2009.
  • 4This report is an official mechanism for Vertex to disseminate its quarterly financial performance to the public.
  • 5The filing itself is procedural, with the substantive financial information contained within the referenced press release.
  • 6No specific operational updates or significant business developments beyond the financial results were detailed in the 8-K itself, but they would be in the press release.

Frequently Asked Questions

The financial results are detailed in the press release filed as Exhibit 99.1 to this Form 8-K. You should refer to that document for specific figures regarding revenue, net income, and other financial metrics for the third quarter of 2009.

This 8-K filing is significant because it officially announces and disseminates Vertex Pharmaceuticals' consolidated financial results for the quarter ended September 30, 2009, to the public and regulatory bodies. It serves as a primary notification for investors to access these key performance indicators.

The Form 8-K itself typically does not contain detailed management commentary. The substantive analysis and discussion of the financial results are usually found in the accompanying press release (Exhibit 99.1) that is incorporated by reference.

Forward-looking statements and any financial guidance for future periods would most likely be found within the press release (Exhibit 99.1) itself, rather than in the brief 8-K filing. Investors should carefully review the press release for any such information.